{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:06:22Z","timestamp":1775091982728,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R37CA248563-01A1"],"award-info":[{"award-number":["1R37CA248563-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) can lead to chemotherapy dose reduction, delay, and discontinuation, and has limited effective prevention strategies. Our study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherapy in people with early-stage breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected baseline data including participants\u2019 age, gender, race, body mass index (BMI), hemoglobin (regular and A1C), thyroid stimulating hormone, Vitamins (B6, B12, and D), anxiety, and depression up to 4 months prior to their first paclitaxel treatment. We also collected CIPN severity by Common Terminology Criteria for Adverse Events (CTCAE) after chemotherapy, chemotherapy relative dose density (RDI), disease recurrence, and mortality rate at the time of the analysis. Logistic regression was used for statistical analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We extracted 105 participants\u2019 baseline characteristics from electronic medical records. Baseline BMI was associated with CIPN severity (Odds Ratio [OR] 1.08; 95% CI, 1.01-1.16, P\u2005=\u2005.024). No significant correlations were observed in other covariates. At median follow-up (61 months), there were 12 (9.5%) breast cancer recurrences and six (5.7%) breast cancer-related deaths. Higher chemotherapy RDI was associated with improved disease-free survival (DFS, OR 1.025; 95% CI, 1.00-1.05; P\u2005=\u2005.028).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions and Relevance<\/jats:title>\n                  <jats:p>Baseline BMI may be a risk factor for CIPN and suboptimal chemotherapy delivery due to CIPN may negatively impact disease-free survival in patients with breast cancer. Further study is warranted to identify mitigating lifestyle factors to reduce incidences of CIPN during breast cancer treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad062","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T18:06:21Z","timestamp":1679940381000},"page":"604-608","source":"Crossref","is-referenced-by-count":13,"title":["Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-7272","authenticated-orcid":false,"given":"Wanqing Iris","family":"Zhi","sequence":"first","affiliation":[{"name":"Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nechama","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"Weill Department of Medicine Cornell Medicine , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexie","family":"Lessing","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renaissance School of Medicine, Stony Brook University , Stony Brook, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylou","family":"Galantino","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Health Sciences, Stockton University , Galloway, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Piulson","sequence":"additional","affiliation":[{"name":"Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Liu","family":"Kot","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine , Bronx, New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Li","sequence":"additional","affiliation":[{"name":"Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-2597","authenticated-orcid":false,"given":"Ting","family":"Bao","sequence":"additional","affiliation":[{"name":"Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"3","key":"2023070520003347400_CIT0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment","volume":"90","author":"Pachman","year":"2011","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"2023070520003347400_CIT0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy.","volume":"20","author":"Zajaczkowska","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"1","key":"2023070520003347400_CIT0003","doi-asserted-by":"crossref","first-page":"e00558","DOI":"10.1002\/brb3.558","article-title":"Chemotherapy-induced neuropathies-a growing problem for patients and health care providers","volume":"7","author":"Banach","year":"2017","journal-title":"Brain Behav"},{"issue":"1","key":"2023070520003347400_CIT0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum neurotoxicity pharmacogenetics","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"2023070520003347400_CIT0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"issue":"2","key":"2023070520003347400_CIT0006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-\u00adinduced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"2023070520003347400_CIT0007","doi-asserted-by":"crossref","first-page":"949","DOI":"10.6004\/jnccn.2019.7290","article-title":"Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments","volume":"17","author":"McCrary","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"issue":"23","key":"2023070520003347400_CIT0008","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol."},{"issue":"28","key":"2023070520003347400_CIT0009","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in \u00adsurvivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol."},{"issue":"13","key":"2023070520003347400_CIT0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA."},{"key":"2023070520003347400_CIT0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.06.008","article-title":"A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients","volume":"101","author":"Bao","year":"2018","journal-title":"Eur J Cancer."},{"key":"2023070520003347400_CIT0012"},{"issue":"2","key":"2023070520003347400_CIT0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11764-021-01012-y","article-title":"The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors","volume":"16","author":"Timmins","year":"2022","journal-title":"J Cancer Surviv"},{"issue":"2","key":"2023070520003347400_CIT0014","doi-asserted-by":"crossref","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"5","key":"2023070520003347400_CIT0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1634\/theoncologist.2018-0298","article-title":"Age and the risk of paclitaxel-induced neuropathy in women with early-stage breast cancer (Alliance A151411): results from 1,881 patients from cancer and leukemia group B (CALGB) 40101","volume":"24","author":"Barginear","year":"2019","journal-title":"Oncologist"},{"key":"2023070520003347400_CIT0016","article-title":"Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review","author":"Timmins","year":"2021","journal-title":"J Cancer Surviv"},{"issue":"2","key":"2023070520003347400_CIT0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jns.12271","article-title":"Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients","volume":"23","author":"Robertson","year":"2018","journal-title":"J Peripher Nerv Syst."},{"issue":"1","key":"2023070520003347400_CIT0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000442527","article-title":"Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy","volume":"90","author":"Ottaiano","year":"2016","journal-title":"Oncology."},{"issue":"10","key":"2023070520003347400_CIT0019","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s11136-017-1635-0","article-title":"The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice","volume":"26","author":"Simon","year":"2017","journal-title":"Qual Life Res."},{"issue":"2","key":"2023070520003347400_CIT0020","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020165","article-title":"Early detection of diabetic peripheral neuropathy: a focus on small nerve fibres.","volume":"11","author":"Burgess","year":"2021","journal-title":"Diagnostics."},{"key":"2023070520003347400_CIT0021"},{"issue":"25","key":"2023070520003347400_CIT0022","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023070520003347400_CIT0023","doi-asserted-by":"crossref","first-page":"pkz078","DOI":"10.1093\/jncics\/pkz078","article-title":"Diabetes and clinical outcome in patients with metastatic colorectal cancer: CALGB 80405 (Alliance)","volume":"4","author":"Brown","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"2023070520003347400_CIT0024","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdp509","article-title":"Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies","volume":"21","author":"Ramanathan","year":"2010","journal-title":"Ann Oncol."},{"issue":"2","key":"2023070520003347400_CIT0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2020.05.026","article-title":"The associations between physical activity, neuropathy symptoms and health-related quality of life among gynecologic cancer survivors","volume":"158","author":"Thomaier","year":"2020","journal-title":"Gynecol Oncol."},{"issue":"2","key":"2023070520003347400_CIT0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpainsymman.2019.04.029","article-title":"Deleterious effects of higher body mass index on subjective and objective measures of chemotherapy-induced peripheral neuropathy in cancer survivors","volume":"58","author":"Petrovchich","year":"2019","journal-title":"J Pain Symptom Manage."},{"key":"2023070520003347400_CIT0027","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.12.006","article-title":"Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy","volume":"73","author":"Lees","year":"2017","journal-title":"Eur J Cancer."},{"issue":"1","key":"2023070520003347400_CIT0028","doi-asserted-by":"crossref","first-page":"e0170814","DOI":"10.1371\/journal.pone.0170814","article-title":"Characterisation of immune and neuroinflammatory changes associated with chemotherapy-\u00adinduced peripheral neuropathy","volume":"12","author":"Makker","year":"2017","journal-title":"PLoS One."},{"key":"2023070520003347400_CIT0029"},{"issue":"5","key":"2023070520003347400_CIT0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer."},{"issue":"1","key":"2023070520003347400_CIT0031","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","article-title":"Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative","volume":"169","author":"Zhang","year":"2018","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2023070520003347400_CIT0032","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.21873\/anticanres.14863","article-title":"Impact of the relative dose intensity of neoadjuvant chemotherapy with anthracycline followed by taxane on the survival of patients with human epidermal growth factor receptor 2-negative breast cancer: the JONIE1 study","volume":"41","author":"Yamada","year":"2021","journal-title":"Anticancer Res."},{"key":"2023070520003347400_CIT0033","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1995.tb31062.x","article-title":"High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts","volume":"770","author":"Fields","year":"1995","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"2023070520003347400_CIT0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","article-title":"Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials","volume":"1","author":"Sparano","year":"2000","journal-title":"Clin Breast Cancer."},{"key":"2023070520003347400_CIT0035","doi-asserted-by":"crossref","first-page":"770663","DOI":"10.3389\/fphar.2021.770663","article-title":"Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/604\/50825903\/oyad062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/604\/50825903\/oyad062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:01:12Z","timestamp":1688587272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/604\/7087215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad062","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,27]]}}}